Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

NCT05427240 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT05427240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05427240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Not applicable
Overall status
Recruiting
Start date
September 28, 2022
Completion date
July 1, 2026
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer